Rofecoxib-induced hepatotoxicity: A forgotten complication of the coxibs

Canadian Journal of Gastroenterology

Volumn 20, Issue 5, 2006, Pages 351-355

  Yan, Brian ^a   Leung, Yvette ^a   Urbanski, Stefan J ^b   Myers, Robert P ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE   (Canada)

Author keywords

Adverse effects; Cholestasis; Coxib; Drug toxicity; Hepatitis; Rofecoxib

Indexed keywords

ROFECOXIB; URSODEOXYCHOLIC ACID;

ADULT; ANAMNESIS; ARTHRALGIA; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL PROTOCOL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; JAUNDICE; KNEE OSTEOARTHRITIS; LIVER BIOPSY; LIVER TOXICITY; MALAISE; MALE; NAUSEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 33745255736     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/356434     Document Type: Article

References (37)

1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
2. Bombardier C, Laine L, Reicin A, et at. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
4. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
5. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-9.
6. Teoh NC, Farrell GC. Hepatotoxicity associated with nonsteroidal anti-inflammatory drugs. Clin Liver Dis 2003;7:401-13.
7. Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: Focus on nimesulide. Drug Saf 2002;25:633-48.
8. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000;7:153-8.
9. Bextra (Valdecoxib) Product Monograph. In: Repchinsky C, ed. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa, Ontario: Canadian Pharmacists Association, 2004-271-6.
10. Vioxx (Rofecoxib) Product Monograph. In: Repchinsky C, ed. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa, Ontario: Canadian Pharmacists Association, 2004:2173-8.
11. Huster D, Schubert C, Berr F, Messner J, Caca K. Rofecoxib-induced cholestatic hepatitis: Treatment with molecular adsorbent recycling system (MARS). J Hepatol 2002;37:413-4.
12. Harsch IA, Michaeli P, Hahn EG, Konturek PC, Klein R. A rare case of rofecoxib-induced cholestatic hepatitis. Dig Liver Dis 2003;35:911-2.
13. Linares P, Vivas S, Jorquera F, Olcoz JL, de Leon B, Oritz de Urbina J. Severe cholestasis and acute renal failure related to rofecoxib. Am J Gastroenterol 2004;99:1622-3.
14. Papachristou GI, Demetris AJ, Rabinovitz M. Acute cholestatic hepatitis associated with long-term use of rofecoxib. Dig Dis Sci 2004;49:459-61.
15. Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis: A case report. Arch Intern Med 2000;160:553-4.
16. Galan MV, Gordon SC, Silverman AL. Celecoxib-induced cholestatic hepatitis. Ann Intern Med 2001;134:254.
17. Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 2001;77:548-50.
18. O'Beirne JP, Cairns SR. Drug Points: Cholestatic hepatitis in association with celecoxib. BMJ 2001;323:23.
19. Alegria P, Lebre L, Chagas C. Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann Intern Med 2002;137:75.
20. Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G. Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 2002;36:1887-9.
21. Zinsser P, Meyer-Wyss B, Rich P. Hepatotoxicity induced by celecoxib and amlodipine. Swiss Med Wkly 2004;134:201.
22. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-10.
23. Lee WN. Assessing causality in drug-induced liver injury. J Hepatol 2000;33:1003-5.
24. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
25. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6.
26. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998;134:1108-12.
27. Regnier S, Descamps V, Boui M, et al. Parvovirus B19 infection mimicking drug-induced hypersensitivity syndrome. Ann Dermatol Venereol 2000;127:505-6.
28. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
29. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-94.
30. Schiodt FV, Lee WM. Fulminant liver disease. Clin Liver Dis 2003;7:331-49.
31. Browne GS, Nelson C, Nguyen T, Ellis BA, Day RO, Williams KM. Stereoselective and substrate-dependent inhibition of hepatic mitochondria beta-oxidation and oxidative phosphorylation by the nonsteroidal anti-inflammatory drugs ibuprofen, flurbiprofen, and ketorolac. Biochem Pharmacol 1999;57:837-44.
32. Bolder U, Trang NV, Hagey LR, et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999;117:962-71.
33. Seitz S, Kretz-Rommel A, Oude Efferink RP, Boetsterli UA. Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 1998;11:513-9.
34. Zhang JY, Zhan J, Cook CS, Ings RM, Breau AP Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism. Drug Metab Dispos 2003;31:652-8.
35. Souto EO, Miyoshi H, Dubois RN, Gores GJ. Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledochovenous fistula rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G805-11.
36. Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001;14:1620-8.
37. Reddy BS, Hirose Y, Luber R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7.